Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's Disease

Introduction: Alzheimer's disease, being the most frequent cause of dementia in elderly people, still is difficult to diagnose and to predict its occurrence. The clinical application of biomarkers for diagnosis of Alzheimer's disease has been restricted so far to the analysis of proteins i...

Full description

Bibliographic Details
Main Author: Walter Fierz
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Aging Neuroscience
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fnagi.2018.00276/full
id doaj-0c6f313de8d54a36be1306dd878ac02e
record_format Article
spelling doaj-0c6f313de8d54a36be1306dd878ac02e2020-11-25T01:29:28ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652018-10-011010.3389/fnagi.2018.00276403818Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's DiseaseWalter FierzIntroduction: Alzheimer's disease, being the most frequent cause of dementia in elderly people, still is difficult to diagnose and to predict its occurrence. The clinical application of biomarkers for diagnosis of Alzheimer's disease has been restricted so far to the analysis of proteins in the cerebrospinal fluid like amyloid β1−42 and p-tau. However, in a recently published nature letter it has been shown that the high-performance measurement of amyloid-β in plasma alone could provide a method well suited for a broad clinical application. The study uses ROC analysis to evaluate the clinical significance of the method but it does not provide likelihood ratios (LR) of the measured results.Methods: In this article, a newly developed method is used to calculate LRs for any measurement result of a study by approximation of the ROC curves using Bézier curves. Such LRs provide an estimation of the clinical significance of any particular test result by applying Bayes' theorem: Pretest odds for disease multiplied by the LR of the test result give the posttest odds.Results: The application of the Bézier curve approximation to the data of the plasma amyloid-β study is demonstrated. To generalize the calculation of LRs for all test results, a relation between the test results and the points on the Bézier curve with their LRs is established.Discussion: The application of Bézier curves in ROC analysis allows calculating LRs for all individual test results when measuring amyloid-β biomarkers for Alzheimer's disease.https://www.frontiersin.org/article/10.3389/fnagi.2018.00276/fullAlzheimer's diseaseBézier curvesbiomarkerslikelihood ratiosROC curves
collection DOAJ
language English
format Article
sources DOAJ
author Walter Fierz
spellingShingle Walter Fierz
Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's Disease
Frontiers in Aging Neuroscience
Alzheimer's disease
Bézier curves
biomarkers
likelihood ratios
ROC curves
author_facet Walter Fierz
author_sort Walter Fierz
title Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's Disease
title_short Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's Disease
title_full Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's Disease
title_fullStr Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's Disease
title_full_unstemmed Application of Bézier Curves for Calculating Likelihood Ratios for Plasma Amyloid-β Biomarkers for Alzheimer's Disease
title_sort application of bézier curves for calculating likelihood ratios for plasma amyloid-β biomarkers for alzheimer's disease
publisher Frontiers Media S.A.
series Frontiers in Aging Neuroscience
issn 1663-4365
publishDate 2018-10-01
description Introduction: Alzheimer's disease, being the most frequent cause of dementia in elderly people, still is difficult to diagnose and to predict its occurrence. The clinical application of biomarkers for diagnosis of Alzheimer's disease has been restricted so far to the analysis of proteins in the cerebrospinal fluid like amyloid β1−42 and p-tau. However, in a recently published nature letter it has been shown that the high-performance measurement of amyloid-β in plasma alone could provide a method well suited for a broad clinical application. The study uses ROC analysis to evaluate the clinical significance of the method but it does not provide likelihood ratios (LR) of the measured results.Methods: In this article, a newly developed method is used to calculate LRs for any measurement result of a study by approximation of the ROC curves using Bézier curves. Such LRs provide an estimation of the clinical significance of any particular test result by applying Bayes' theorem: Pretest odds for disease multiplied by the LR of the test result give the posttest odds.Results: The application of the Bézier curve approximation to the data of the plasma amyloid-β study is demonstrated. To generalize the calculation of LRs for all test results, a relation between the test results and the points on the Bézier curve with their LRs is established.Discussion: The application of Bézier curves in ROC analysis allows calculating LRs for all individual test results when measuring amyloid-β biomarkers for Alzheimer's disease.
topic Alzheimer's disease
Bézier curves
biomarkers
likelihood ratios
ROC curves
url https://www.frontiersin.org/article/10.3389/fnagi.2018.00276/full
work_keys_str_mv AT walterfierz applicationofbeziercurvesforcalculatinglikelihoodratiosforplasmaamyloidbbiomarkersforalzheimersdisease
_version_ 1725096918353182720